FINGOLIMOD

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category Free-form
ATC L04AA27
UNII 3QN8BYN5QF
EPA CompTox DTXSID40167363

Structure

InChI Key KKGQTZUTZRNORY-UHFFFAOYSA-N
Smiles CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1
InChI
InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C19H33NO2
Molecular Weight 307.48
AlogP 3.2
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 12.0
Polar Surface Area 66.48
Molecular species BASE
Aromatic Rings 1.0
Heavy Atoms 22.0
Assay Description Organism Bioactivity Reference
In vitro ability to inhibit mouse allogenic mixed leukocyte response (MLR) Mus musculus 6.1 nM
Compound was tested for its effect on mouse allogenic mixed lymphocyte reaction(MLR). Mus musculus 67.4 nM
Displacement of [33P]sphingosine 1 phosphate from human S1P1 receptor expressed in CHO cells Homo sapiens 840.0 nM
Antiangiogenic activity in chick embryo chorioallantoic membrane assessed as number of eggs showing 3 mm avascular zone at 100 ug Gallus gallus 100.0 %
Antiangiogenic activity in chick embryo chorioallantoic membrane assessed as number of eggs showing 3 mm avascular zone at 10 ug Gallus gallus 77.0 %
Antiangiogenic activity in chick embryo chorioallantoic membrane assessed as number of eggs showing 3 mm avascular zone at 1 ug Gallus gallus 40.0 %
Immunosuppressive activity in BALB/c/C57BL/6 mouse T cells assessed as inhibition of alloantigen-induced cell proliferation after 96 hrs by measuring [3H]thymidine uptake by mixed lymphocyte reaction assay Mus musculus 6.1 nM
Agonist activity at human S1P1 receptor expressed in human U2OS cells co-expressing eGFP assessed as receptor internalization into cytoplasm using Hoechst dye staining Homo sapiens 2.0 nM
Agonist activity at S1P5 receptor (unknown origin) Homo sapiens 0.3 nM
Agonist activity at S1P4 receptor (unknown origin) Homo sapiens 0.3 nM
Agonist activity at S1P3 receptor (unknown origin) Homo sapiens 3.0 nM
Agonist activity at S1P1 receptor (unknown origin) Homo sapiens 0.3 nM
Induction of bradycardia in Wistar Imamichi rat assessed as reduction in heart rate 10 mg/kg, po after 24 hrs Rattus norvegicus 24.1 %
Agonist activity at human S1P1 receptor expressed in EDG1-bla U2OS cells incubated for 18 hrs prior to GenBlazer substrate addition by beta-arrestin recruitment assay Homo sapiens 7.2 nM
Reduction in IL2 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method Mus musculus 68.0 %
Reduction in IFNgamma gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method Mus musculus 30.0 %
Reduction in CD11b gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method Mus musculus 45.0 %
Reduction in CD4 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method Mus musculus 60.0 %
Reduction in B220 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method Mus musculus 55.0 %
Reduction in Fcgr4 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method Mus musculus 25.0 %
Reduction in Ifit1 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method Mus musculus 16.0 %
Reduction in OASL2 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method Mus musculus 7.0 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 21.73 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 5.71 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.13 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.33 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.13 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.33 %

Cross References

Resources Reference
ChEBI 63115
ChEMBL CHEMBL314854
DrugBank DB08868
DrugCentral 4167
FDA SRS 3QN8BYN5QF
Guide to Pharmacology 2407
KEGG D10001
PubChem 107970
SureChEMBL SCHEMBL7445
ZINC ZINC000001542002
CONTENTS